share_log

科濟藥業-B：自願公告 - 於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會上呈列的CT041研究成果更新

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT041 AT 2024 ASCO GI MEETING

香港交易所 ·  Jan 18 19:00
Summary by Moomoo AI
科济药业-B（股份代號：2171）於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會（ASCO GI）上發表了其CAR-T細胞候選產品satri-cel（研發代號：CT041）的1b期臨床試驗結果更新。該研究針對Claudin18.2陽性的晚期胃癌╱食管胃結合部腺癌（GC/GEJ）或胰腺癌（PC）患者，評估satri-cel的安全性和有效性。研究結果顯示，satri-cel整體安全性良好，未觀察到劑量限制性毒性（DLT）或治療相關死亡，並在某些患者中達到了完全緩解。目前，2期臨床試驗正在進行中，並已確定600×106個細胞為2期推薦劑量（RP2D）。科济药业表示，satri-cel作為首個自體Claudin18.2 CAR T細胞療法，在多重治療後的晚期GC/GEJ和PC患者中展現出前景。公司致力於成為全球生物製藥的領導者，為全球癌症患者帶來創新和差異化的細胞療法。
科济药业-B（股份代號：2171）於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會（ASCO GI）上發表了其CAR-T細胞候選產品satri-cel（研發代號：CT041）的1b期臨床試驗結果更新。該研究針對Claudin18.2陽性的晚期胃癌╱食管胃結合部腺癌（GC/GEJ）或胰腺癌（PC）患者，評估satri-cel的安全性和有效性。研究結果顯示，satri-cel整體安全性良好，未觀察到劑量限制性毒性（DLT）或治療相關死亡，並在某些患者中達到了完全緩解。目前，2期臨床試驗正在進行中，並已確定600×106個細胞為2期推薦劑量（RP2D）。科济药业表示，satri-cel作為首個自體Claudin18.2 CAR T細胞療法，在多重治療後的晚期GC/GEJ和PC患者中展現出前景。公司致力於成為全球生物製藥的領導者，為全球癌症患者帶來創新和差異化的細胞療法。
Kozai Pharmaceuticals-B (stock code: 2171) announced a Phase 1b clinical trial update of its CAR-T cell candidate product satri-cel (R&D code: CT041) at the 2024 American Society of Clinical Oncology Annual Conference on Gastrointestinal Oncology (ASCO GI). The study evaluated the safety and efficacy of satri-cel in patients with Claudin18.2-positive late-stage gastric/gastroesophageal combined prostate cancer (GC/GEJ) or pancreatic cancer (PC). The results showed that satri-cel had good overall safety, with no dose-limiting toxicity (DLT) or treatment-related death observed, and complete relief was achieved in some patients. Currently, a 2-phase clinical trial is underway and 600×106 cells have been identified as the Phase 2 Recommended Dose (RP2D). As the first autologous Claudin18.2 CAR T cell therapy, satri-cel shows promise in patients with late GC/GEJ and PC after multiple treatments, said Kozai Pharmaceuticals. The company is committed to being a global leader in biopharmaceuticals, bringing innovative and differentiated cell therapies to cancer patients worldwide.
Kozai Pharmaceuticals-B (stock code: 2171) announced a Phase 1b clinical trial update of its CAR-T cell candidate product satri-cel (R&D code: CT041) at the 2024 American Society of Clinical Oncology Annual Conference on Gastrointestinal Oncology (ASCO GI). The study evaluated the safety and efficacy of satri-cel in patients with Claudin18.2-positive late-stage gastric/gastroesophageal combined prostate cancer (GC/GEJ) or pancreatic cancer (PC). The results showed that satri-cel had good overall safety, with no dose-limiting toxicity (DLT) or treatment-related death observed, and complete relief was achieved in some patients. Currently, a 2-phase clinical trial is underway and 600×106 cells have been identified as the Phase 2 Recommended Dose (RP2D). As the first autologous Claudin18.2 CAR T cell therapy, satri-cel shows promise in patients with late GC/GEJ and PC after multiple treatments, said Kozai Pharmaceuticals. The company is committed to being a global leader in biopharmaceuticals, bringing innovative and differentiated cell therapies to cancer patients worldwide.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more